Mirum Pharmaceuticals

MIRM

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$2.4m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$117.07

+26.7% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+44.1%Q3 ’25

+7.7%Q4 ’25

+17.0%Q1 ’26

+26.7%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

1Q2 ’25

1Q3 ’25

1Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Mirum Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Mirum Pharmaceuticals

Polen Capital Management	0.0%$2.4m	$2.4m	Added +1.8%	5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Mirum Pharmaceuticals
		Bought or sold				Filing
14 Sep 2026	Bjerkholt EricCHIEF FINANCIAL OFFICER	▼ Sold	9,943	$98.37	$978k	Form 4
2 Sep 2026	Howe JolandaSVP, GLOBAL CONTROLLER	▼ Sold	658	$100.00	$66k	Form 4
1 Sep 2026	Peetz ChristopherCHIEF EXECUTIVE OFFICER	▼ Sold	21,688	$98.91	$2.1m	Form 4
1 Sep 2026	Peetz ChristopherCHIEF EXECUTIVE OFFICER	▼ Sold	8,312	$98.08	$815k	Form 4
18 Aug 2026	Howe JolandaSVP, GLOBAL CONTROLLER	▼ Sold	40,000	$100.00	$4.0m	Form 4
11 Aug 2026	Bjerkholt EricCHIEF FINANCIAL OFFICER	▼ Sold	6,001	$99.90	$600k	Form 4
10 Aug 2026	Peetz ChristopherCHIEF EXECUTIVE OFFICER	▼ Sold	11,683	$98.51	$1.2m	Form 4
10 Aug 2026	Peetz ChristopherCHIEF EXECUTIVE OFFICER	▼ Sold	6,017	$99.25	$597k	Form 4
10 Aug 2026	Peetz ChristopherCHIEF EXECUTIVE OFFICER	▼ Sold	2,300	$100.14	$230k	Form 4
3 Aug 2026	Howe JolandaSVP, GLOBAL CONTROLLER	▼ Sold	1,840	$105.29	$194k	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 65m at 31 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

2019

$0k2020

$19.1m2021

$77.1m2022

$186m2023

$337m2024

$521m2025

Mirum Pharmaceuticals revenue and net income by year
Year	Revenue	Net income
2025	$521m	−$23.4m
2024	$337m	−$87.9m
2023	$186m	−$163m
2022	$77.1m	−$136m
2021	$19.1m	−$84.0m
2020	$0k	−$103m
2019	–	−$52.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.